TNF Muteins and Uses Thereof

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

USPTO granted Patent US12605425B2 to Oxford University Innovation Limited for tumour necrosis factor (TNF) muteins that function as selective agonists of tumour necrosis factor receptor 1 (TNFR1). The patent covers compositions comprising these TNF muteins, methods of treating or detecting tumours, and related nucleic acids and host cells. This is a routine patent grant conferring exclusive rights to the assignee with no immediate compliance obligations for other parties.